Pericarditis Recurrence After Initial Uncomplicated Clinical Course
Section snippets
Methods
We conducted a retrospective review through an informatics engine–based search of electronic health records to create a database that includes patients admitted with a first episode of acute pericarditis at the Virginia Commonwealth University Medical Center (Richmond, Virginia) from 2009 to 2018. The method of the search has been previously described in detail.6 According to the last European Society of Cardiology guidelines, the diagnosis of acute pericarditis requires at least 2 of the 4
Results
A total of 240 patients met acute pericarditis criteria. Among them, 164 patients (68%) had an uncomplicated course, and 76 patients (32%) had an acute complicated clinical course. In patients with an uncomplicated clinical course, the median age was 50 (interquartile range 32 to 62) years, 43% were women, and 48% were Black. Pericarditis was considered idiopathic in 84 patients (51%), and 58 patients (35%) had post–cardiac surgery injury pericarditis. All patients were free of symptoms at
Discussion
We herein report the outcomes of patients hospitalized for a first uncomplicated episode of acute pericarditis in a large urban hospital in the United States: 9% of patients experienced a pericarditis recurrence in the following 6 months, with subacute presentation and younger age being independent predictors. Subacute presentation was defined as symptoms occurring over several days without a clear-cut acute onset. Patients with subacute presentation had already been reported to be at higher
Disclosures
Dr. Abbate has served as a consultant for AstraZeneca, Effetti, Implicit Biosciences, Kiniksa, Janssen, Merck, Novartis, Olatec, and Serpin Pharma. Dr. Vecchié received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 American Heart Association Scientific Sessions. Dr. Bonaventura received a travel grant from Kiniksa Pharmaceuticals Ltd. to attend the 2019 American Heart Association Scientific Sessions. The other authors have no conflicts of interest to disclose.
References (15)
- et al.
Management of acute and recurrent pericarditis: JACC state-of-the-art review
J Am Coll Cardiol
(2020) - et al.
Health-related quality of life in patients with recurrent pericarditis: results from a phase 2 study of rilonacept
BMC Cardiovasc Disord
(2021) - et al.
Clinical presentation and outcomes of acute pericarditis in a large urban hospital in the United States of America
Chest
(2020) - et al.
Exercise is good for the heart but not for the inflamed pericardium?
JACC Cardiovasc Imaging
(2019) - et al.
Complicated pericarditis: understanding risk factors and pathophysiology to inform imaging and treatment
J Am Coll Cardiol
(2016) - et al.
Sex-based differences in prevalence and clinical presentation among pericarditis and myopericarditis patients
Am J Emerg Med
(2017) - et al.
Indicators of poor prognosis of acute pericarditis
Circulation
(2007)
Cited by (4)
Pathogenic pathways and therapeutic targets of inflammation in heart diseases: A focus on Interleukin-1
2024, European Journal of Clinical InvestigationNovel Pathophysiological, Diagnostic and Therapeutic Concepts in Acute and Recurrent Pericarditis
2023, Reviews in Cardiovascular MedicineAdvances in Imaging and Targeted Therapies for Recurrent Pericarditis: A Review
2022, JAMA CardiologyAdvances in pharmacotherapy for acute and recurrent pericarditis
2022, Expert Opinion on Pharmacotherapy
Drs. Del Buono and Vecchié contributed equally to this work.
This study was supported in part by a grant from Kiniksa Pharmaceuticals Ltd. to Dr. Gal and Dr. Abbate, and by the Bio-informatics Core of the institutional CTSA Award No. UL1TR002649 from the National Center for Advancing Translational Sciences (to Dr. Gal). Dr. Abbate received support from the Sapienza Visiting Professor Programme 2020 of the Sapienza Università di Roma, Italy. Research funding for this work was also generously provided by Drs. Claudia and Richard Balderston.